First drug in its class and works within 3-5 days. Best home run I have seen since AVNR, another one that idiot AF got wrong (cough mixture lol).
Had a fresh look and the highest moving averages are now at 5.74 (241 and 242 week moving averages). That is the escape velocity price to 10. As long as the stock keeps rising a bit every day it will eventually breakout as shorts throw the towel in.
Historically over the years this stock has hung out between 2.5 and 6.5 which is the resistance trading is chewing through now. Once over 6 which is about the 5 year moving average and highest of the moving averages the stock will become much more lively. The good news is that there is enough trading volume at the moment to chew up this resistance within weeks. Obviously quick FDA approval will accelerate this process ;-).
Funny but I took it as a buying opportunity as it was obvious to me that the drop was unwarranted but then again that's the difference between you and me, you chase high market gainers, I predict them ;-). There is now a big gap to 5 that will be filled now which is another bonus of that 2014 drop.
p.s. I know your passive-aggressive MO well from your IMSC behavior, you are just bashing here so you can get a lower entry price ;-).
IPO price was 6.50 on Dec 22, 1997
Dilution has taken place since to get the product to the end-zone but those higher numbers just may be reached again now ;-).
Intel's integrated graphics are getting better and better leaving AMD with very little to offer now except price.
The kind of bounce you get when a gap is filled, from 27.96 on Jun 12th 2014, as I predicted last week
Jun 13, 2014 29.75 30.06 29.56 29.87 122,194,300 29.06
Jun 12, 2014 27.86 28.10 27.77 27.96 31,211,400 27.20
The adjusted gap (due to dividends) is actually down to 27.20 so there is still more bounce powder dry :). As I told Marco when he was touting 25 you also have 20 year moving averages lurking around 26 which also will provide further support.
The only people selling are you shorties and quick profit-takers. True Longs are locked and loaded because they know this is a $10-20 stock in the long term. They have been developing this drug for over a decade.
Previous phase failures were due to testing technicalities not because the drug does not work which was pretty obvious to me reading the PRs.
FDA Approval is a cinch and the market is huge for a safe one-shot drug ! You should know by now I only pick winners williamszxz ;-).
I think it is more important to remember it was 5,75 in the past year only on good Phase II results ! :-0)
It is just stabilizing before the next leg up.Soon there will be analyst upgrades and institutions buying into this.
Give it time, today is just the glorious start on the way to multiple double figures over the coming years. These drugs are for real for both BPH and CANCER !
'Their drugs clearly work for both cancer and BPH and it is just a matter of time before this is proven beyond doubt and their drugs get approved for use. Eventual stock price target, $10.'
In addition, the following advantages of the new drug are highlighted:
Safety profile highly superior to existing treatments. Minimal or no sexual, hormonal or cardiovascular or other debilitating side effects.
Reduced cancer risk in Phase 2 data: U.S. Phase 2 data showing therapeutic effect of fexapotide on prostate cancer. Phase 2 data showed fexapotide treated low grade localized prostate cancer (Gleason 3+3 or less) had statistically significant less progression compared to controls. By comparison, some commonly used older approved BPH treatments have been linked to increased cancer risk.
Enhanced compliance and patient convenience compared to oral medications. Fexapotide is given as a single painless office treatment injectable. Older approved oral medications generally involve daily pills intended for the rest of the patient’s life.